The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jian Li - Evercore ISI Institutional Equities, Research Division - Analyst
: Great. Can you guys hear me?
Question: Jian Li - Evercore ISI Institutional Equities, Research Division - Analyst
: This is Jian for Mahaney. Just a couple of questions. First question, just on PTR. To clarify, if you can kind of walk through like the magnitude of the
grocer impact in the next few quarters, are we expecting this to kind of moderate through the next couple of quarters? And I think you said that
by Q4 of this year, we should fully comp that impact. So just to confirm that. And also maybe just like how should we think about like ex-grocer
growing 16% year-over-year. How should we think about the exit rate of this business in a more normalized kind of condition?
Question: Jian Li - Evercore ISI Institutional Equities, Research Division - Analyst
: Great. And then if I may, one follow-up on probably a bigger picture question on the pharma advertising the man sol. So what is required to scale
this business? Or maybe asked another way, like what is the kind of the current investment most focused on? Is it adding experience sales, building
a better ad tech platform, better measurement, et cetera? So if you could just kind of talk through the investment priorities here? Thank you.
Question: Jailendra P. Singh - Truist Securities, Inc., Research Division - Analyst
: So my first question is around provider mode where you have 450,000 prescribers engaging with the company since launch. Maybe provide some
details around the engagement level? Like which tools have you seen the highest engagement? Is it a cost comparison or coupon sharing or news
feeds? I'm trying to understand like the scale needed in this part of the business where you can go to pharma manufacturers to get more aggressive
with your bids for launches or campaign. Clearly, you're competing with some other players who talk about ROIs in the range of 10 is to 1 for their
pharma clients. So trying to understand if with the risk of being too early on your pitch in this part of the business.
Question: Jailendra P. Singh - Truist Securities, Inc., Research Division - Analyst
: And my quick follow-up on the -- thanks for the color on the 2Q outlook by segment. But can you share your updated revenue growth expectations
by segment for the full year. Are those unchanged? Or any changes there beyond the 10 million POS discount we called out?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 10, 2023 / 12:00PM, GDRX.OQ - Q1 2023 Goodrx Holdings Inc Earnings Call
|
